MAp44: Emerging Insights into Its Role in Disease Pathogenesis and Association with Various Diseases.

Abstract

The MBL-associated protein of 44 kilodaltons (MAp44) belongs to the MBL-associated serine proteases (MASP) family, which is important in regulating the complement system's alternative pathway. MAp44 has been discovered to interact with complement components in numerous autoimmune illnesses leading to complement dysregulation and amplification of inflammatory reactions. These findings imply that MAp44 could be a biomarker for disease conditions and a therapeutic target for reducing complement-mediated illness. Furthermore, recent findings reveal that MAp44 has a role in cancer genesis and progression. Its participation in tumor immune evasion, angiogenesis, and metastasis has been revealed in studies, underlining its potential as a prognostic marker and a prospective target for cancer treatment. MAp44 targeting may boost immune surveillance, decrease tumor development, and improve patient outcomes in a variety of cancers. Recent research has revealed its participation in a variety of disease processes, indicating it as a possible contributor to disease etiology. The developing understanding of MAp44's role lays the groundwork for future study and development of targeted treatment approaches. Understanding the complicated processes behind its participation in autoimmune illnesses, cancer, and cardiovascular diseases opens up new possibilities for diagnosis, prognosis, and therapy approaches. Exploiting MAp44's therapeutic potential might open the door for innovative therapies targeted at improving patient outcomes in a variety of illnesses. This review gives a comprehensive knowledge of the role of MAp44 in diseases and its therapeutic potential.